Hip Replacement Surgery — Cost, Top Hospitals & Success Rates | MyMedicPlus

Total hip replacement (total hip arthroplasty, THA) is one of the most successful surgical procedures in modern medicine. The operation removes the worn surfaces of the hip joint — the arthritic femoral head and the damaged acetabular cartilage — and replaces them with a prosthetic implant consisting of an acetabular cup (shell and liner), a femoral stem, and a femoral head. The result is a pain-free, mechanically stable joint that allows patients to return to walking, cycling, swimming, and most low-impact activities within weeks to months. Over one million hip replacements are performed globally each year, and national joint registries consistently report implant survival rates exceeding 95% at 10 years and 85–90% at 20 years with modern implant designs.

The primary indication is end-stage osteoarthritis of the hip, where cartilage loss is advanced enough to cause constant pain, severe functional limitation, and failure of all conservative management strategies. Additional indications include rheumatoid arthritis, post-traumatic arthritis following acetabular or femoral fractures, avascular necrosis (osteonecrosis) of the femoral head, hip dysplasia with secondary arthritis, and failed prior hip surgery. Patient selection, implant choice, surgical approach, and surgeon volume are the key determinants of outcome, with high-volume surgeons (>100 THAs/year) demonstrating significantly lower complication, dislocation, and revision rates.

Modern total hip replacement has been transformed by several concurrent advances: minimally invasive and anterior approaches that spare major muscle groups; highly cross-linked polyethylene (HXLPE) liners that reduce wear from ~200 microns/year to <20 microns/year; ceramic-on-ceramic and oxidised zirconium bearing surfaces for patients under 60; computer-assisted and robotic surgery for precise component positioning; and rapid recovery (enhanced recovery after surgery, ERAS) protocols enabling same-day or next-day discharge. These advances have pushed revision rates to historic lows and expanded the procedure to younger, more active patients.

• Primary hip osteoarthritis — progressive cartilage loss causing joint space narrowing, osteophyte formation, subchondral sclerosis, and severe groin, thigh, or buttock pain unresponsive to conservative treatment
• Rheumatoid arthritis of the hip — inflammatory joint destruction with synovitis, erosion, and often bilateral involvement; may require simultaneous or staged bilateral replacement
• Post-traumatic arthritis — arthritis secondary to acetabular fractures, femoral neck or head fractures, or hip dislocation; often requires complex acetabular reconstruction
• Avascular necrosis (osteonecrosis) of the femoral head — segmental collapse of the femoral head due to ischaemia; causes from corticosteroid use, alcohol, sickle cell disease, radiation, or idiopathic causes
• Developmental dysplasia of the hip (DDH) — secondary arthritis from congenital or childhood hip dysplasia; may require augmented acetabular components or structural bone grafting
• Ankylosing spondylitis with hip involvement — inflammatory arthropathy causing progressive loss of hip motion and functional limitation
• Paget's disease of bone — metabolic bone disease causing hip deformity and secondary arthritis
• Failed prior hip procedures — conversion arthroplasty after failed hip arthroscopy, failed internal fixation of hip fractures (hemiarthroplasty conversion), or core decompression for AVN
• Femoral neck fractures in elderly patients — hemiarthroplasty or total hip replacement for displaced subcapital fractures

Ideal candidates have radiographically confirmed end-stage hip arthritis (Tönnis Grade 3; joint space <2 mm or complete loss), severe pain significantly affecting quality of life (Oxford Hip Score <20/48), functional limitation despite optimised non-surgical management (physiotherapy, weight loss, walking aids, analgesics, and intra-articular injections), and sufficient bone stock and soft tissue integrity to support implant fixation. There is no strict upper age limit — patients in their 80s and 90s benefit significantly when medically optimised; surgical risk is stratified by comorbidity burden (ASA score) rather than age alone.

Relative contraindications and caution flags:

• Active infection — systemic or local infection (skin, urinary tract) must be eradicated before elective implant surgery to prevent periprosthetic joint infection (PJI)
• Morbid obesity (BMI >40) — associated with significantly higher PJI rates (up to 4×), mechanical failure, and dislocation; most centres recommend weight reduction before surgery
• Neuromuscular conditions — Parkinson's disease, cerebral palsy, or muscular dystrophy increase dislocation risk; posterior-stabilised or constrained designs may be needed
• Severe osteoporosis — compromises cemented and uncemented fixation; bisphosphonate optimisation may be warranted pre-operatively
• Uncontrolled systemic disease — poorly controlled diabetes, cardiac disease, or immunosuppression must be optimised before elective surgery
• Active malignancy — life expectancy and oncological treatment plans must be considered before elective joint replacement

Surgical approaches:

Posterior (Moore/Southern) approach — the most widely used worldwide; provides excellent acetabular visualisation; traditional posterior capsulotomy carries a dislocation rate of ~2–3%, reduced to <1% with capsular repair and calcar-guided component positioning.

Direct anterior approach (DAA) — muscle-sparing interval between tensor fascia lata and sartorius; associated with faster short-term recovery, reduced dislocation risk, and earlier weight-bearing; technically demanding and requires a specialised table or leg positioner; learning curve of 50–100 cases.

Direct lateral (Hardinge) approach — splits the gluteus medius and minimus; reliable visualisation but carries a small risk of abductor weakness affecting gait; commonly used in revision surgery.

Minimally invasive (2-incision technique) — allows component implantation through two small incisions; technically challenging; advantages over single-incision anterior approach are marginal in experienced hands.

Implant fixation:

• Uncemented (cementless) fixation — porous-coated or hydroxyapatite-coated implants achieve biological bone ingrowth; preferred for patients under 65 with good bone quality; allows earlier weight-bearing with modern designs
• Cemented fixation — polymethylmethacrylate (PMMA) bone cement provides immediate stable fixation; preferred in elderly patients with osteoporosis or when uncemented fixation is unreliable; 'gold standard' for femoral stem in patients over 75 in the UK (NJR guidelines)
• Hybrid fixation — uncemented cup + cemented stem; balances cup bone-ingrowth with femoral cement stability; widely used in the UK and Australia

Bearing surface options:

• Ceramic-on-highly cross-linked polyethylene (CoHXLPE) — current gold standard for most patients; excellent wear characteristics, safe debris profile, low dislocation rate with large heads
• Ceramic-on-ceramic (CoC) — lowest wear rate; risk of audible squeaking (1–3%); risk of ceramic fracture (<0.01%); suited for very active patients under 55
• Oxidised zirconium on HXLPE — combines low wear ceramic-like surface on a metal substrate; excellent option for patients requiring MRI and for those at risk of ceramic fracture
• Metal-on-polyethylene (MoP) — traditional bearing; largely replaced by ceramic heads; cobalt-chrome heads still used with HXLPE in some revision scenarios

Robotic and computer-assisted surgery: Robotic systems (Mako, VELYS, Cori) use pre-operative CT-based 3D planning and intraoperative real-time guidance to achieve precise cup inclination (target 40° ± 5°) and anteversion (15° ± 5°), significantly reducing outlier positioning rates and associated dislocation and wear risks.

Total hip replacement consistently delivers some of the highest patient satisfaction scores in elective surgery:

• Pain relief: 90–95% of patients report significant or complete pain relief at 1 year; improvement sustained at 10 and 20 years in the majority
• Functional improvement: Oxford Hip Score improves by an average of 20–24 points postoperatively; most patients resume walking, stairs, light exercise, and independent activities of daily living within 6–12 weeks
• Implant longevity: Modern implants (HXLPE + ceramic head, uncemented cup) show 97% survival at 10 years and 90–92% at 20 years per the Australian Orthopaedic Association National Joint Replacement Registry (AOANJRR 2024)
• Quality of life: EQ-5D scores improve significantly; depression, sleep disturbance, and social isolation related to chronic pain resolve in the majority
• Activity level: Most patients return to walking, cycling, swimming, and golf; low-impact sports are permitted from 3 months; high-impact activities (running, contact sports) are discouraged to protect implant longevity
• Cost-effectiveness: One of the most cost-effective elective procedures per quality-adjusted life year (QALY) gained across all surgical specialties (NICE HTA guidance)

Total hip replacement is safe but major elective surgery; patients must be counselled regarding the following risks:

• Deep vein thrombosis (DVT) and pulmonary embolism (PE): DVT occurs in 1–3% despite prophylaxis; symptomatic PE in 0.5–1%; fatal PE in <0.1%. Standard thromboprophylaxis includes low-molecular-weight heparin or aspirin combined with mechanical compression stockings and early mobilisation.
• Periprosthetic joint infection (PJI): The most feared complication; occurs in 0.5–2% of primary THAs; treatment requires prolonged antibiotics and often two-stage revision surgery. Pre-operative decolonisation (Staphylococcus aureus screening and decolonisation) reduces risk.
• Dislocation: 1–2% with posterior capsular repair; slightly higher in neuromuscular patients. Usually treated with closed reduction under sedation; recurrent dislocation may require revision to a constrained or dual-mobility liner.
• Leg length discrepancy: Residual discrepancy of >1 cm in up to 2–5% of cases; careful intraoperative templating and trial reduction reduce incidence.
• Nerve injury: Sciatic or femoral nerve palsy in <1%; usually resolves; permanent deficit is rare (<0.1%).
• Intraoperative fracture: Periprosthetic fracture during insertion occurs in 0.1–1%; more common in osteoporotic bone and revision surgery.
• Implant loosening (aseptic loosening): Main cause of late revision; incidence significantly reduced with modern bearing surfaces and uncemented fixation; 10-year revision rate ~5%.
• Heterotopic ossification: Abnormal bone formation around the hip in 2–5%; NSAIDs or low-dose radiation used prophylactically in high-risk patients.

Hospital phase (Days 1–5): Under enhanced recovery (ERAS) protocols, patients stand and take steps on the day of surgery. A physiotherapist supervises walking with a frame or crutches, stair practice, and hip precaution education. Blood transfusion requirements have been reduced to <5% with modern tranexamic acid protocols. Most patients are discharged home at 2–5 days; fit, home-supported patients may be discharged at 24 hours (day-surgery THA programmes).

Early recovery (Weeks 1–6): Patients progress from a walking frame to crutches and then to a stick as pain and balance improve. Hip precautions (posterior approach: avoid hip flexion >90°, adduction past midline, and internal rotation) are observed for 6 weeks or until muscle strength is restored. Driving resumes at 6 weeks (left hip) or when right-hip reaction time normalises on a medical test. Outpatient physiotherapy 2–3 times/week.

Intermediate recovery (Weeks 6–12): Most patients walk independently and climb stairs confidently. Stationary cycling begins at 6–8 weeks; swimming at 6–8 weeks (once the wound is healed). Return to desk work at 6–12 weeks; manual work at 3–6 months.

Long-term (3–12 months): Strength, endurance, and proprioception continue to improve for 6–12 months. Low-impact sports (cycling, swimming, golf, doubles tennis) are typically permitted at 3–4 months. High-impact activities (running, heavy contact sports) are discouraged permanently to protect bearing surfaces.

Follow-up schedule: 6 weeks (wound, X-ray, weight-bearing review), 3 months (functional review), 1 year (clinical and radiographic assessment), then every 3–5 years for implant surveillance. Patient-reported outcomes (Oxford Hip Score) are collected at 6 months and 1 year per joint registry requirements.

Total hip replacement costs include surgeon fee, anaesthesiologist fee, hospital stay, operating theatre and implant costs, and post-operative physiotherapy. Implant costs alone range from USD 3,000 (standard implants) to USD 15,000+ (ceramic-on-ceramic, robotic-assisted). International cost benchmarks:

• United States: USD 30,000–55,000 (inpatient); USD 20,000–35,000 (ambulatory surgery centre)
• United Kingdom: GBP 10,000–18,000 (private); NHS average wait 12–18 months
• India: USD 4,500–9,000 — Apollo Hospitals, Fortis, Medanta, and Manipal offer robotic THA with imported implants; 80–85% cost savings vs. USA
• Thailand: USD 8,000–15,000 — Bumrungrad, Samitivej, and Bangkok Hospital offer JCI-accredited orthopaedic centres
• Turkey: USD 6,000–12,000 — strong infrastructure for international patients with premium ceramic implant options
• Mexico: USD 8,000–16,000 — popular for North American patients; hospitals in Monterrey and Mexico City offer international-standard orthopaedic care
• Hungary / Czech Republic: EUR 8,000–14,000 — high surgical quality, EU regulatory standards, short travel for UK/European patients

Total cost of a medical tourism trip (surgery + implant + 2-week stay + flights + physiotherapy) from the US to India is typically USD 8,000–14,000 vs. USD 35,000–55,000 domestically — representing savings of 60–80%.

• Physiotherapy and exercise: Targeted hip strengthening, gait training, and aquatic therapy can reduce pain by 20–40% in mild-to-moderate arthritis and delay the need for surgery by years; most effective when started early
• Analgesics and NSAIDs: Paracetamol, ibuprofen, celecoxib — effective for pain control; long-term NSAID use carries cardiovascular and GI risks in older patients
• Intra-articular corticosteroid injection: Provides 3–6 months symptomatic relief in 50–70% of patients; not disease-modifying; repeated injections (>3) may accelerate cartilage loss
• Intra-articular hyaluronic acid (viscosupplementation): Evidence mixed; some benefit in mild-to-moderate hip OA; not routinely recommended by NICE for hip OA (unlike knee OA)
• Platelet-rich plasma (PRP): Autologous growth factor injection; emerging evidence of 6–12 month benefit in early hip OA; not yet standard of care
• Hip osteotomy: Pelvic (Ganz PAO) or femoral osteotomy to correct deformity and redistribute load — suitable for younger patients (<45) with dysplasia or focal cartilage loss in a well-aligned compartment; delays but does not prevent eventual arthroplasty
• Hip resurfacing arthroplasty: Conserves more proximal femoral bone than THA; best suited to active males under 60 with good bone quality; discussed in the companion guide
• Partial hip replacement (hemiarthroplasty): Replaces only the femoral head; reserved for femoral neck fractures in elderly patients; not appropriate for hip arthritis as the native acetabulum continues to degrade